BioRestorative Therapies, Inc. announced that the FDA has cleared its Investigational New Drug application for BRTX-100, marking it as the first stem cell product candidate approved for evaluation in ...
MELVILLE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results